RxDoctor Payments Data

Vincent Morgan, APRN

Adult Health · Little Rock, ARNPI 1235770942

Payments from drug & device makers

$557in general payments, 2019–2025

Across 22 payments — averaging $25.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$363
  • GSK$84
  • Novartis$47
  • Teva Pharmaceuticals USA, Inc.$16
  • Novo Nordisk$16
  • Merck$15
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$557100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca10$363
GSK5$84
Novartis3$47
Teva Pharmaceuticals USA, Inc.1$16
Novo Nordisk1$16
Merck1$15
Pfizer1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$557 in reported general payments places this provider in the 45th percentile of 154 adult health providers in Arkansas.

See all adult health providers in Arkansas

Medicare billing

Part B allowed, 2024
$19,909
Medicare patients
79
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$90,886
JardianceEmpagliflozin83$68,026
EliquisApixaban56$44,777
FarxigaDapagliflozin Propanediol44$40,839
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$28,169
JanuviaSitagliptin Phosphate16$20,288
EntrestoSacubitril/Valsartan19$18,686
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,253
LinzessLinaclotide12$7,447
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$7,189
Albuterol Sulfate HfaAlbuterol Sulfate179$4,984
SymbicortBudesonide/Formoterol Fumarate21$4,827
Levemir FlexpenInsulin Detemir23$4,664
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$4,491
PremproEstrogen,con/M-Progest Acet12$3,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$90,88686 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$363$53,92079 claims
PfizerEliquis, Prempro$15$47,78768 claims
GSKTrelegy Ellipta$84$28,16941 claims
MerckJanuvia$15$20,28816 claims
NovartisEntresto$47$18,68619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 154 adult health providers in Arkansas.

Other adult health in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →